Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Another scammer...
Hey Mike, you're a bit late to the scammers party!
Investor News: Investigation of certain Directors of Anavex Life Sciences Corp. (NASDAQ:AVXL) over possible Wrongdoing
?Michael Daniels ?Mar 31, 2016 ?Big Business, Business
An investigation for investors in NASDAQ:AVXL shares concerning potential breaches of fiduciary duties by certain directors of Anavex Life Sciences Corp. was announced.
Investors who are current long term investors in Anavex Life Sciences Corp. (NASDAQ:AVXL) shares, have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 – 1554.
The investigation by a law firm for current investors in NASDAQ:AVXL stocks follows a lawsuit filed recently against Anavex Life Sciences Corp. over alleged securities laws violations. The investigation on behalf of current long term investors in NASDAQ:AVXL stocks, concerns whether certain Anavex Life Sciences directors are liable in connection with the allegations made in that lawsuit.
The plaintiff alleges that the defendants made allegedly false and/or misleading statements and/or allegedly failed to disclose that Anavex had used a paid stock promoter to artificially inflate the Company’s share price and that as a result of the foregoing, Anavex’s public statements were materially false and misleading at all relevant times.
On December 29, 2015, pre-market, Anavex Life Sciences Corp. (NASDAQ:AVXL) disclosed that it had received a subpoena from the U.S. Securities and Exchange Commission(“SEC”) on December 22, 2015. Anavex Life Sciences Corp. stated, in part, that “[t]he Company believes the subpoena and investigation relate to the recent unusual activity in the market for the Company’s shares.” Shares of Anavex Life Sciences Corp. (NASDAQ:AVXL) declined on December 31, 2015, to $4.60 per share.
Those who purchased NASDAQ:AVXL shares have certain options and should contact the Shareholders Foundation.
Contact:
Shareholders Foundation, Inc.
Michael Daniels
3111 Camino Del Rio North – Suite 423
92108 San Diego
Phone: +1-(858)-779-1554
Fax: +1-(858)-605-5739
mail@shareholdersfoundation.com
We simply don't know what he presented today until someone digs it up. The fact that the Dr. is familiar with 2-73, as well as its benefits in cognition with AD patients and has commented favorably on 2-73 in the past, might suggest he mention it in his presentation on cognition. I would certainly like to see his presentation.
What will it take, you ask? I think you know... an Anavex PR on the 12-wk data!
Good post! I concur. To further add... there will likely be differing dosage requirements of both 2-73 and donepezil (if prescribed), depending upon the patient, which would suggest they be prescribed separately.
Agreed! It's just waiting for the fuse to be lit!
Most investors already know this...
CogState-DIGITAL BIOMARKERS CONFERENCE
Paul Maruff will be speaking during the AD session March 31 1:15 pm
"Professor Paul Maruff, Chief Scientific Officer of Cogstate commented: “The Cogstate tests measure people’s ability to store and use information. The results of the Phase 2a study demonstrate that ANAVEX 2-73 improves psychomotor function, attention and working memory. For attention and working memory these improvements were statistically significant..."
Paul Maruff will be speaking during the AD session today at 1:15 pm. If anyone finds info, please post... TIA!
Is the short interest still around 10% (3.5M sh)?
Josh, NEWSFLASH! Nothing goes straight up without news.
Really? You just said that it's "dead money" and "there are better opportunities elsewhere." Do you not follow your own advice?
I'm certain he was referring to ownership. Dr. M wouldn't make such a claim about patentability until it's granted.
Partnership will happen this year, according to Missling. Or perhaps with a large government grant, they won't need a partnership!
I would bet it's fast tracked... 2 years at the MOST!
On August 12, 2015, Anavex announced that it has received a Notice of Allowance from the U.S. Patent and Trademark Office for U.S. Pat. App. No. 14/205,637 related to ANAVEX 2-73. Upon issuance, the patent will provide intellectual property protection until at least 2030.
If Dr. M doesn't issue his PR or news by 3/31, then we sure don't want him to issue it on April 1st! haha :)
If the final rejection states that the combination of 2-73 and donepezil is "obvious" by one knowledgeable in the art (as stated in the non-final rejection) then that means no other AD drug can be patented with donepezil, either.
It's also a moot point, since the company has determined that the results are the same with or without donepezil.
Paul Maruff will be speaking during the AD session March 31 1:15 pm
"Professor Paul Maruff, Chief Scientific Officer of Cogstate commented: “The Cogstate tests measure people’s ability to store and use information. The results of the Phase 2a study demonstrate that ANAVEX 2-73 improves psychomotor function, attention and working memory. For attention and working memory these improvements were statistically significant..."
Might Missling be in attendance, and might 12-wk results be presented then or prior to the conference? We shall see...
One of these days, the $4s will be a price of the past, never to be seen again. It might very well be this week.
Was the premarket telling us it's going to $5 today? We'll see...
Seems everyone who wants shares before next week already has them. Surprised this didn't walk up and stay up today.
BTW... I messaged IR to request that, if 12-wk data won't be announced before the end of the month, then PLEASE provide a PR to explain why and when to expect it.
I'll let everyone know if I get a response.
Not yet... There's plenty of time today to start buying.
Though, we'd get the most "bang for the buck" if the release was on Monday. Releasing AH today would not have as much impact (unless the news is extremely outstanding), due to weekend delay.
Well... that would certainly make for a Good Friday!
If it comes this month, I'm thinking Monday morning. Seems they typically release news on a Monday.
IMO, they want to discourage retail on these takedowns, so that the next time it's up 5% they're hoping you'll sell. They want your shares!
Not yet....
Yeah, very quiet today... chatter mimics volume.
Last time to buy this low today...$4.61
North of $4.75, IMO...perhaps $4.90.
Some signals don't involve much volume.
MMs grabbing some stop-loss shares before the ride up.
Pardon me... After Hours.
That premarket spike is telling us something...
This week is much like last week when news did not come on Monday. The anticipated walk up, at the end of the prior week, was met with selling (manipulated and otherwise) the 1st half of the following week. We should see short covering and other buying tomorrow in anticipation of a possible PR on Monday.
We all know it's coming... it's just a matter of when!
We're in the same boat... it will be a year on April 9th that I made my first and largest purchase in my taxable acct.
Sitting in a stock for years is usually not a good strategy...with a few exceptions. AVXL might be one of them, but there will still be opportunities to swing trade it after good news. Trading around a core position is a common method.
Glad that the swinging has worked out for you. Me, I'm waiting at least for the data...possibly until a partnership (or other), then re-evaluate. We're just too close to news for me to try to get cute with the trading.
Fortunate timing...
Just hope you're not out when the PR comes...
Hindsight is always 20/20, but what kept you in is the uncertainty of when the long-awaited PR comes out. Can't afford to miss that binary event. You'll be able to sell much higher than $5.60 when that happens.
Very interesting... thanks!